Adicet Bio Inc. (NASDAQ:ACET) went down by -2.88% from its latest closing price compared to the recent 1-year high of $21.87. The company’s stock price has collected -1.55% of loss in the last five trading sessions. The Wall Street Journal reported on 12/06/21 that Bitcoin, Coinbase, Shiba Inu, Alibaba: What to Watch in the Stock Market Today
Is It Worth Investing in Adicet Bio Inc. (NASDAQ :ACET) Right Now?
Plus, the 36-month beta value for ACET is at 2.15. Opinions of the stock are interesting as 11 analysts out of 11 who provided ratings for Adicet Bio Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $28.09, which is $10.89 above the current price. ACET currently public float of 38.35M and currently shorts hold a 9.35% ratio of that float. Today, the average trading volume of ACET was 552.80K shares.
ACET’s Market Performance
ACET stocks went down by -1.55% for the week, with a monthly jump of 5.65% and a quarterly performance of 14.44%, while its annual performance rate touched 80.86%. The volatility ratio for the week stands at 6.92% while the volatility levels for the past 30 days are set at 7.48% for Adicet Bio Inc. The simple moving average for the period of the last 20 days is -5.81% for ACET stocks with a simple moving average of 12.85% for the last 200 days.
Analysts’ Opinion of ACET
Many brokerage firms have already submitted their reports for ACET stocks, with JP Morgan repeating the rating for ACET by listing it as a “Overweight.” The predicted price for ACET in the upcoming period, according to JP Morgan is $23 based on the research report published on September 21st of the current year 2022.
SMBC Nikko, on the other hand, stated in their research note that they expect to see ACET reach a price target of $28. The rating they have provided for ACET stocks is “Outperform” according to the report published on March 31st, 2022.
Truist gave a rating of “Buy” to ACET, setting the target price at $30 in the report published on March 08th of the current year.
ACET Trading at 4.00% from the 50-Day Moving Average
After a stumble in the market that brought ACET to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.35% of loss for the given period.
Volatility was left at 7.48%, however, over the last 30 days, the volatility rate increased by 6.92%, as shares surge +1.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.60% lower at present.
During the last 5 trading sessions, ACET fell by -1.55%, which changed the moving average for the period of 200-days by +26.56% in comparison to the 20-day moving average, which settled at $18.27. In addition, Adicet Bio Inc. saw -1.66% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ACET starting from Aftab Blake, who sale 6,967 shares at the price of $21.00 back on Nov 10. After this action, Aftab Blake now owns 28,209 shares of Adicet Bio Inc., valued at $146,307 using the latest closing price.
Schor Chen, the President & CEO of Adicet Bio Inc., sale 30,000 shares at $20.06 during a trade that took place back on Nov 10, which means that Schor Chen is holding 53,424 shares at $601,920 based on the most recent closing price.
Stock Fundamentals for ACET
Current profitability levels for the company are sitting at:
- -631.38 for the present operating margin
The net margin for Adicet Bio Inc. stands at -637.19. Equity return is now at value -18.20, with -16.30 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 17.31.